Limit to Benefits of Large Reductions in Low-Density Lipoprotein Cholesterol Levels: Use of Fractional Polynomials to Assess the Effect of Low-Density Lipoprotein Cholesterol Level Reduction in Metaregression of Large Statin Randomized Trials
A recent metaregression 1 of 25 large statin randomized trials involving 155 613 participants and 23 791 major vascular events reported a significant reduction in the risk of major vascular events associated with a reduction in low-density lipoprotein cholesterol (LDL-C) level. The question that naturally follows is whether there is a threshold for the benefit of LDL level reduction that can be achieved with statins or whether greater reductions in LDL level would bring greater reductions in vascular events.
Conventional metaregressions such as the one by Delahoy et al, 1 however, rely on "linear" modeling, which assumes that the association fits a line (a constantly increasing or decreasing risk as the exposure increases or decreases) and does not allow for alternative associations such as threshold effects. We performed a "flexible" (not "linear") unrestricted maximum-likelihood metaregression (inverse variance-weighted regression) based on fractional polynomials 2 of the reduction in LDL-C level on the logarithmic relative risk (RR) for major vascular events.
Methods.
The mean absolute reduction in LDL-C level at 1 year and the RR for major vascular events were abstracted from each individual randomized trial included in the recent metaregression.
1 First-order and secondorder fractional polynomial models take the forms log RR = ␤ 1 ϩ ␤ 2 x p and ␤ 1 ϩ ␤ 2 x p ϩ ␤ 3 x q , respectively. By choosing p and q from the predefined set {-2, -1, -0.5, 0, 0.5, 1, 2, 3}, a rich set of possible functions, including some so-called U-shaped and J-shaped relations, may be accommodated. The powers are expressed according to the Box-Tidwell transformation, in which x p denotes x p if p 0 and log x if p=0. 2 When p=q, the model becomes
. For each set of powers (p, q), we calculated ␤ 1 , ␤ 2 , and ␤ 3 that minimized the deviance (sum of inverse varianceweighted squared residuals) using Microsoft Excel Solver (Microsoft Corp). The best fit among the family of models thus generated is defined as that with the highest likelihood or, equivalently, that with the lowest deviance. The gain for a given model is defined as the deviance associated with the reference linear model (␤ 1 =0, p = 1; applied in the recent metaregression 1 ) minus that for the model in question; accordingly, a larger gain indicates a better fit. Discussion. Our fractional polynomials metaregression suggests almost no additional benefit in the use of statins beyond a 40 mg/dL decrease in LDL-C level in preventing major vascular events.
A traditional method of summarizing dose-response relations across studies is to estimate the change in the logarithm of the RR per unit of exposure within each study and to combine these estimates across studies. Such an approach could be misleading, however, because it assumes that the dose-response relation follows a specific model form, usually linear. 3 Polynomial models, typically quadratic models, are used to represent nonlinearity. 4 An alternative curve-fitting method, fractional polynomial regression, 5 has been described. Fractional polynomials are a family of models to consider, as covariates, power transformations of a continuous exposure variable restricted to a small, predefined set of integer and noninteger exponents.
2 Such approaches are underused in epidemiologic research and have seldom 6 been compared in a meta-analysis of dose-response aggregate data. Fractional polynomials provide great flexibility for a meta-analysis of doseresponse aggregate data and are especially valuable when important nonlinearity is anticipated. 2 Furthermore, they are easier to communicate mathematically, require the estimation of fewer parameters, and are less influenced by arbitrariness in the choice of the model than traditional approaches.
On the basis of the Cholesterol Treatment Trialists' meta-analysis, 7 Sniderman et al 8 calculated that any potential gain from increasing the dose of atorvastatin calcium from 40 to 80 mg would be small, at best an additional 2% reduction in clinical events. The increase in dose, unfortunately, would likely be associated with increased adverse effects and decreased adherence. Accordingly, whether net benefit would be demonstrable cannot be assumed. It follows that definitive evidence supporting maximal lowering of LDL-C level or maximal dose of statins is still lacking and that guidelines, if they are to be evidence based, should acknowledge this uncertainty. 8 Although we found, on the basis of flexible (not linear) metaregression, that using statins to reduce LDL-C level by more than approximately 40 mg/dL could produce almost no additional reduction in the risk of major vascular events, further analysis would be required to confirm our findings. 
